Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 3462
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT01804647 LOMBARD — Longitudinal Therapeutically Non-interventional Study of MSRV… |
LOMBARD — Longitudinal Therapeuti… | SEP | À vérifier | COMPLETED | En attente / non publié | GeNeuro Innovation SAS | France, Spain, Switzerland · Centre Hospitalier Unive… | 2012-11 → 2015-02 | Ouvrir |
| NCT04480307 ProTEct-MS — Clinical Trial Assessing Temelimab Following Rituximab Tre… |
Temelimab 18 mg/kg | SEP | Phase 2 | COMPLETED | En attente / non publié | GeNeuro Innovation SAS | Sweden · Center for Neurology, Academic Specialist Ce… | 2020-06-17 → 2022-01-24 | Ouvrir |
| NCT05054140 CALLIPER — Study to Evaluate Efficacy, Safety, and Tolerability of IMU-… |
IMU-838 | SEP | Phase 2 | UNKNOWN | En attente / non publié | Immunic AG | United States, Bulgaria, Canada, Czechia, Germany, Mo… | 2021-09-30 → 2025-01-07 | Ouvrir |
| NCT03239860 ANGEL-MS — Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in… |
GNbAC1 Monoclonal Antibody | SEP | Phase 2 | TERMINATED | En attente / non publié | GeNeuro SA | Bulgaria, Croatia, Czechia, Estonia, Germany, Hungary… | 2017-06-06 → 2018-11-14 | Ouvrir |
| NCT03179423 RAINBOW-T1D — Clinical Trial Assessing the GNbAC1 in Patients With Onse… |
GNbAC1 | SEP | Phase 2 | COMPLETED | En attente / non publié | GeNeuro Innovation SAS | Australia · AIM Centre, Merewether, Australia | Barwo… | 2017-06-14 → 2019-05-07 | Ouvrir |
| NCT07161258 FENerations1 — A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety a… |
Fenebrutinib | SEP | Phase 2 | RECRUITING | En attente / non publié | Hoffmann-La Roche | Argentina, Brazil, Mexico, Poland, Portugal, Spain, U… | 2025-10-06 → 2029-02-13 | Ouvrir |
| NCT04586010 FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib … |
Fenebrutinib | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Argentina, China, Dominican Republic, … | 2021-03-17 → 2027-11-30 | Ouvrir |
| NCT04586023 FENhance 2 — Study to Evaluate the Efficacy and Safety of Fenebrutinib … |
Fenebrutinib | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Austria, Brazil, Bulgaria, Canada, Den… | 2021-03-24 → 2027-07-09 | Ouvrir |
| NCT06890923 TILS-022 — Nasal Foralumab in Patients With Non-Active Secondary Progre… |
Foralumab TZLS-401 100 µg | SEP | Phase 2 | RECRUITING | En attente / non publié | Tiziana Life Sciences LTD | United States · Brigham and Women's Hospital, Boston,… | 2025-03-04 → 2026-08-30 | Ouvrir |
| NCT03993171 REPAIR-MS — 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaire… |
gold nanocrystals | SEP | Phase 2 | COMPLETED | En attente / non publié | Clene Nanomedicine | United States · University of Texas Southwestern, Dal… | 2019-12-19 → 2025-07-31 | Ouvrir |
| NCT03536559 VISIONARY-MS — Nanocrystalline Gold to Treat Remyelination Failure in C… |
CNM-Au8 | SEP | Phase 2 | TERMINATED | En attente / non publié | Clene Nanomedicine | United States, Australia, Canada · Alfred Health, Mel… | 2018-11-23 → 2022-07-12 | Ouvrir |
| NCT06083753 VISTA — Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjec… |
PIPE-307 Dose A | SEP | Phase 2 | COMPLETED | En attente / non publié | Janssen Research & Development, L… | United States · Alta Bates Summit Medical Center, Ber… | 2023-11-06 → 2025-08-04 | Ouvrir |
| NCT04478591 WOC — The Wearing-off Phenomenon of Ocrelizumab in Patients With Multip… |
WOC — The Wearing-off Phenomenon … | SEP | À vérifier | COMPLETED | En attente / non publié | Amsterdam UMC, location VUmc | Netherlands · Amsterdam UMC, location VUmc, Amsterdam… | 2020-05-12 → 2021-05-01 | Ouvrir |
| NCT04676555 TIMIOS — Time and Motion Study for Ocrelizumab and Ofatumumab Administr… |
Ocrelizumab | SEP | À vérifier | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States, Australia · Novartis Investigative Sit… | 2021-05-11 → 2021-10-21 | Ouvrir |
| NCT05131984 Ocrelizumab Access by Socio-Economic Status |
Ocrelizumab | SEP | À vérifier | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States · Brigham and Women's Hospital, Boston,… | 2021-11-18 → 2023-07-01 | Ouvrir |
| NCT05528666 Risk Perception in Multiple Sclerosis |
Risk Perception in Multiple Scler… | SEP | À vérifier | COMPLETED | En attente / non publié | Novartis Pharmaceuticals | United States · Novartis Investigative Site, East Han… | 2021-09-09 → 2021-09-17 | Ouvrir |
| NCT06127095 A Study to Assess New Participant's Perspectives Beyond Clinical Effica… |
A Study to Assess New Participant… | SEP | À vérifier | COMPLETED | En attente / non publié | Biogen | United States · Biogen, Cambridge, United States | 2023-11-24 → 2024-11-28 | Ouvrir |
| NCT05210621 CONSONANCE EX — LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELI… |
Ocrelizumab | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | France · Amiens University Hospital, Amiens, France |… | 2022-03-08 → 2029-02-24 | Ouvrir |
| NCT07207148 People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agoni… |
GLP-1 | SEP | À vérifier | RECRUITING | En attente / non publié | Northwestern University | United States · Northwestern Memorial Hospital, Chica… | 2025-11-15 → 2028-08-31 | Ouvrir |
| NCT05974839 Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With … |
Effect of Ocrelizumab on Cortical… | SEP | À vérifier | COMPLETED | En attente / non publié | State University of New York at B… | United States · Buffalo Neuroimaging Analysis Center,… | 2023-10-01 → 2024-02-28 | Ouvrir |
| NCT05974852 ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patien… |
ORATORIO-CP — Effect of Ocrelizum… | SEP | À vérifier | COMPLETED | En attente / non publié | State University of New York at B… | United States · Buffalo Neuroimaging Analysis Center,… | 2023-10-01 → 2023-12-30 | Ouvrir |
| NCT04293458 ESOGUARDBE1 — Efficacy of EsoGuard on Samples Collected Using EsoCheck … |
EsoGuard | SEP | NA | COMPLETED | En attente / non publié | Lucid Diagnostics, Inc. | United States, Spain · Lucid Investigative Site, Chap… | 2020-02-28 → 2022-08-22 | Ouvrir |
| NCT04295811 ESOGUARDBE2 — Efficacy of EsoGuard Assay on Esophageal Surface Cells Co… |
EsoGuard (lab assay) | SEP | NA | UNKNOWN | En attente / non publié | Lucid Diagnostics, Inc. | United States, Netherlands · Lucid Investigative Site… | 2020-06-18 → 2023-12 | Ouvrir |
| NCT07609537 ICLDR-NAR Tria — Imagery Control Therapy and Lucid Dreaming for REM-Rel… |
ICLDR-NAR Tria — Imagery Control … | SEP | NA | COMPLETED | En attente / non publié | Institute of Behavioral Sleep Med… | Colombia · Bahavioral Sleep Medicine Institute, Medel… | 2024-03-01 → 2025-06-15 | Ouvrir |
| NCT01194570 ORATORIO — A Study of Ocrelizumab in Participants With Primary Progress… |
Ocrelizumab | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States, Australia, Austria, Belgium, Brazil, B… | 2011-03-02 → 2022-12-31 | Ouvrir |